ADULT;
ARTICLE;
BLOOD SAMPLING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSSOVER PROCEDURE;
CYTOKINE PRODUCTION;
DIARRHEA;
DIZZINESS;
DRUG MEGADOSE;
HEADACHE;
HOT FLUSH;
HUMAN;
HUMAN EXPERIMENT;
LOW DRUG DOSE;
LYMPHOCYTE PROLIFERATION;
MALE;
MONOTHERAPY;
NAUSEA;
NORMAL HUMAN;
RANDOMIZED CONTROLLED TRIAL;
SINGLE DRUG DOSE;
T LYMPHOCYTE;
T LYMPHOCYTE ACTIVATION;
BLOOD;
DOSE RESPONSE;
DRUG COMBINATION;
DRUG EFFECTS;
DRUG INTERACTION;
LYMPHOCYTE ACTIVATION;
METABOLISM;
ADULT;
BIOMARKERS, PHARMACOLOGICAL;
CYCLOSPORINE;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG COMBINATIONS;
DRUG INTERACTIONS;
HUMANS;
LYMPHOCYTE ACTIVATION;
MALE;
PYRROLES;
QUINAZOLINES;
T-LYMPHOCYTES;
The first-in-class oral protein kinase C inhibitor AEB071 prolongs renal allograft survival in nonhuman primates and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies
Wagner J, Evenou J-P, Zenke G, et al. The first-in-class oral protein kinase C inhibitor AEB071 prolongs renal allograft survival in nonhuman primates and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies. [Abstract] Transplantation 2006; 82(Suppl 3): 86.
AEB071, a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, everolimus or FTY720
Bruns C, Pally C, Beerli C, et al. AEB071, a novel oral inhibitor of early T-cell activation, prolongs rat cardiac allograft survival when used alone and in combination with cyclosporine, everolimus or FTY720. [Abstract] Transplantation 2006; 82(Suppl 3): 316.
Immunosuppression: Evolution in practice and trends 1994-2004
Meier-Kriesche HU, Li S, Gruessner RWG, et al. Immunosuppression: evolution in practice and trends 1994-2004. Am J Transplant 2006; 6(Part 2): 1111-1131.
AEB071, a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine
Bigaud M, Wieczorek G, Riesen S, et al. AEB071, a novel oral inhibitor of early T-cell activation, prolongs the survival of non-human primate kidney allografts when used as monotherapy or at non-effective doses combined with a non-effective dose of cyclosporine. [Abstract] Transplantation 2006; 82(Suppl 3): 250.
Improved dose linearity of cyclosporin pharmacokinetics from a microemulsion formulation
Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporin pharmacokinetics from a microemulsion formulation. Pharm Res 1994; 11: 301-304.
Potential therapeutic option for psoriasis with AEB071, a novel protein kinase C inhibitor
Skvara H, Dawid M, Kleyn CE, et al. Potential therapeutic option for psoriasis with AEB071, a novel protein kinase C inhibitor. J Clin Invest 2008; 118: 3151-3159.
